AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive ...
Zacks Investment Research on MSN
AstraZeneca gets FDA nod for new hypertension drug Baxfendy
AstraZeneca AZN announced that the FDA has approved baxdrostat for treating adult patients with uncontrolled or ...
AstraZeneca Plc’s new hypertension pill won US Food and Drug Administration approval in a boost for the drugmaker that’s ...
When you think of high blood pressure, lifestyle choices around nutrition or exercise may come to mind—not your hormones. But ...
Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease – RADNOR, Pa., May 18, 2026 (G ...
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor ...
The FDA has approved baxdrostat (Baxfendy), the first oral aldosterone synthase inhibitor, for adults with uncontrolled ...
New drug Baxdrostat lowers stubborn high blood pressure in difficult-to-treat patients, showing promising results in a global ...
The FDA approved the first-in-class oral aldosterone synthase inhibitor baxdrostat (Baxfendy) to treat adults with uncontrolled hypertension in combination with other antihypertensive drugs, ...
Please provide your email address to receive an email when new articles are posted on . Aldosterone is associated with an increased risk of chronic kidney disease progression and the development of ...
A steroid hormone called aldosterone is linked to an increased risk of kidney failure in patients with chronic kidney disease (CKD), according to a study published in the European Heart Journal today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results